Lilly, Foghorn part ways; Wave’s FDA-approved plans

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 01 Oct, 16:04 UTC

The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

science

Sources

• T2Lilly, Foghorn part ways; Wave’s FDA-approved plansBioPharma Dive / Healthcare Dive / MedTech Dive01 Oct, 16:04